Pfenex to Present at the Jefferies 2019 London Healthcare Conference
November 06 2019 - 4:10PM
Pfenex Inc. (NYSE American: PFNX) today announced that Eef
Schimmelpennink, President and Chief Executive Officer, will be
presenting at the Jefferies 2019 London Healthcare Conference on
Wednesday, November 20th, taking place at the Waldorf Hilton in
London.
Conference: |
Jefferies 2019
London Healthcare Conference |
Date: |
Wednesday, November 20, 2019 |
Time: |
4:00 p.m. GMT (8:00 a.m. PST) |
Webcast: |
Interested parties can access the live audio webcast and
archive from the Investors Section of Pfenex's website at
www.pfenex.com |
About Pfenex Inc.
Pfenex is a development and licensing
biotechnology company focused on leveraging its Pfēnex Expression
Technology® to develop and improve protein therapies for unmet
patient needs. Using the patented Pfēnex Expression Technology
platform, Pfenex has created an advanced pipeline of potential
therapeutic equivalents, and vaccines. Pfenex’s lead product
candidate is PF708, a therapeutic equivalent candidate to Forteo®
(teriparatide injection). PF708 has been approved in the U.S.
for the treatment of osteoporosis in certain patients at high risk
of fracture, and marketing authorization applications are pending
in other jurisdictions. In addition, Pfenex is developing
hematology/oncology products in collaboration with Jazz
Pharmaceuticals, including PF743, a recombinant crisantaspase, and
PF745, a recombinant crisantaspase with half-life extension
technology. Pfenex also uses its Pfēnex Expression Technology
platform to produce CRM197, a diphtheria toxoid carrier protein
used in prophylactic and therapeutic vaccines.
Pfenex investors and others should note that
Pfenex announces material information to the public about Pfenex
through a variety of means, including its website
(http://www.pfenex.com/), its investor relations website
(http://pfenex.investorroom.com/), press releases, SEC filings,
public conference calls, corporate Twitter account
(https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company Contact:Susan A. KnudsonChief Financial
Officer(858) 352-4324sknudson@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Sep 2023 to Sep 2024